Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J

June 6, 2020 2:33 AM UTC

UCB buying Engage for $125M
UCB S.A. (Euronext:UCB) acquired Engage Therapeutics Inc. Friday, gaining Staccato alprazolam, a drug-inhaler combo in Phase II testing for the rapid termination of epileptic seizures. Engage will receive $125 million up front and is eligible for up to $145 million in milestones.

Expanded label for Merck’s Recarbrio
FDA approved Recarbrio relebactam/imipenem/cilastatin from Merck & Co. Inc. (NYSE:MRK) to treat hospital-acquired or ventilator-associated bacterial pneumonia in adults. The antibiotic combo is already approved for complicated intra-abdominal and urinary tract infections...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article